logo-loader

NetScientific portfolio company Vortex presents study to combine technology with impedance spectroscopy

Published: 07:51 08 Nov 2018 GMT

Cells and test tubes
The study will be presented at the NanoBiotech Montreux 2018 conference in Switzerland

NetScientific PLC (LON:NSCI) said its portfolio company, Vortex BioSciences, has presented a study demonstrating how its technology can combine with impedance spectroscopy to improve the analysis of circulating tumour cells (CTCs).

The healthcare IP commercialisation group said the study, presented at the NanoBiotech Montreux 2018 conference in Switzerland, introduced the coupling of Vortex’s technology with an impedance chip for counting and sizing cancer cells isolated from blood samples.

READ: NetScientific portfolio company Vortex enters manufacturing partnership with STRATEC

The researchers believed the results of the study provided feasibility for label-free, reliable, fully-integrated cell enumeration, whilst keeping the cells collected intact for downstream transcriptomic, genomic or proteomic analysis.

Impedance spectroscopy involves applying a wave frequency to a system or surface and measuring the changes and is often used on various types of biological tissue.

Francois Martelet, chief executive of NetScientific and chairman of Vortex, said Vortex’s technology was “ready to be adopted by large pharmaceutical players” following the creation of an automated and reliable process and the signing of a manufacturing agreement with German firm STRATEC for its VTX-1 liquid biopsy platform in November.

Wanda Health discusses its recent AI developments

Wanda Health Inc CEO Tom Smith visits the Proactive London studio to speak with Thomas Warner after the Remote Patient Monitoring (RPM) company announced the start of a new fundraise. Smith gives an overview of what Wanda intends to do with the proceeds, highlighting the company's sharp focus...

on 16/1/24